This study is to find out the imaging marker and the changing laws of the marker during the course of the disease. The final purpose is to provide scientific evidence for new prevention, diagnosis and treatment of Alzheimer's disease.

It is an urgent problem in the field of cognitive neuroscience to tell the conversion progression of amnestic mild cognitive impairment(aMCI) patients with Apolipoproteinε4(APOEε4) to Alzheimer's Disease(AD). Based on our preliminary work, we will study the special group of aMCI patients with APOEε4 with multi-modality magnetic resonance imaging (resting-state functional MRI, structural MRI and diffusion tensor imaging) longitudinally. Besides, we will also detect the APOE genotype of each sample and enlarge the sample size. According to situation of the conversion or non-conversion and differences in the conversion progression, we will analyze the data between the inter-groups and intra-groups, compare the imaging data of baseline and follow-up, find the prediction imaging marker of AD and optimize the reliability and validity.

Inclusion Criteria:

• Complaint about memory loss and confirmed by an informant
• Cognitive impairment in single or multiple domains, adjusted for age and education
• Normal or near-normal performance on general cognitive function and no or minimum impairment of daily life activities
• A Clinical Dementia Rating (CDR) score is 0.5
• Failure to meet the criteria for dementia
• Carrying susceptible gene APOEε4
• Must be able to accept examination of MRI, sight and hearing allow to complete test

Exclusion Criteria:

• Other diseases that cause cognitive impairment,such as thyroid disease,stroke and so on
• people who have severe visual and hearing impairment

aMCI patients with APOEε4